within Pharmacolibrary.Drugs.ATC.R;

model R01AD59
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0006666666666666666,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.3,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AD59</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mometasone is a potent synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is commonly used in combination with other agents for nasal administration to treat symptoms of allergic rhinitis and nasal polyps. Mometasone is approved and widely used in many countries in nasal spray formulations, often combined with other agents such as azelastine.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult healthy individuals after nasal administration, as no direct published PK data on mometasone combination nasal sprays (R01AD59) are available. Estimates are based on known PK characteristics for nasal mometasone furoate.</p><h4>References</h4><ol><li><p>Patel, P, et al., &amp; Tantry, SK (2018). Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. <i>Allergy and asthma proceedings</i> 39(3) 232–239. DOI:<a href=\"https://doi.org/10.2500/aap.2018.39.4134\">10.2500/aap.2018.39.4134</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29669668/\">https://pubmed.ncbi.nlm.nih.gov/29669668</a></p></li><li><p>Patel, P, et al., &amp; Tantry, SK (2018). Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. <i>Allergy and asthma proceedings</i> 39(3) 224–231. DOI:<a href=\"https://doi.org/10.2500/aap.2018.39.4133\">10.2500/aap.2018.39.4133</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29669667/\">https://pubmed.ncbi.nlm.nih.gov/29669667</a></p></li><li><p>Wolthers, OD (2013). New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. <i>Recent patents on inflammation &amp; allergy drug discovery</i> 7(3) 223–228. DOI:<a href=\"https://doi.org/10.2174/1872213x113079990019\">10.2174/1872213x113079990019</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23862774/\">https://pubmed.ncbi.nlm.nih.gov/23862774</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AD59;
